S. Y. Gong

This study identifies two potent neutralizing antibodies, EH3 and EH8, from a pediatric patient that cross-neutralize SARS-CoV-2 variants and provide in vivo protection against the Delta VOC.

VE607 inhibits SARS-CoV-2 infection by stabilizing the RBD in the 'up' conformation and blocking S-ACE2 interaction across multiple variants.

This study evaluates how plasma from individuals with a 16-week interval between BNT162b2 mRNA vaccine doses recognizes and neutralizes the Omicron Spike compared to other variants.

The paper examines B and T cell immunity responses to a 16-week interval BNT162b2 vaccine regimen, finding robust immune memory and functional associations between immune components.

The paper evaluates how single mutations in SARS-CoV-2 Spike protein affect antigenicity and ACE2 binding in emerging variants.

This study characterizes two SARS-CoV-2 antibodies effective against variants, showing their structural basis and mechanisms of neutralization.

This study investigates how temperature affects SARS-CoV-2 Spike protein affinity for ACE2, finding increased binding at low temperatures, which is mitigated by the N501Y mutation.

This study shows a single dose of the BNT162b2 mRNA vaccine elicits strong antibody and T cell responses, including Fc-mediated effector functions, and boosts pre-existing immunity in previously infected individuals.

This study tracks humoral immune responses in convalescent individuals up to 8 months post-SARS-CoV-2 infection, showing that IgG+ memory B cells persist while plasma antibody levels decline.